Nautilus Biotechnology (NAUT) Research & Development (2020 - 2026)

Nautilus Biotechnology has disclosed Research & Development across 7 years of filings, most recently posting $9.6 million for Q2 2026.

• In Q2 2026, Research & Development fell 7.51% year-over-year to $9.6 million; the TTM figure through Jun 2026 stood at $38.5 million (down 18.16% YoY), while the FY2025 annual figure was $41.1 million, down 18.56% from the prior year.
• Research & Development came in at $9.6 million for Q2 2026 at Nautilus Biotechnology, down from $9.7 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $12.9 million in Q1 2024 to a low of $8.9 million in Q2 2022.
• Average Research & Development over 5 years is $10.9 million, with a median of $10.6 million recorded in 2023.
• Year-over-year, Research & Development soared 99.75% in 2022 and declined 25.33% in 2025.
• Over 5 years, Research & Development stood at $9.6 million in 2022, then surged by 30.03% to $12.5 million in 2023, then increased by 2.86% to $12.8 million in 2024, then decreased by 25.33% to $9.6 million in 2025, then gained by 0.4% to $9.6 million in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $9.6 million in Q2 2026, $9.7 million in Q1 2026, and $9.6 million in Q4 2025.